Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HBM Holdings Ltd. ( (HK:2142) ) has shared an update.
HBM Holdings Ltd. announced that it will present Phase II clinical data for its anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab, at the ESMO Congress 2025. This presentation will highlight the efficacy and safety of the treatment for microsatellite stable metastatic colorectal cancer, potentially enhancing the company’s position in the oncology market.
More about HBM Holdings Ltd.
HBM Holdings Ltd. operates in the biotechnology industry, focusing on the development of innovative antibody therapies. The company specializes in fully human heavy-chain-only antibodies, with a market focus on treating various solid tumors using advanced therapeutic platforms.
Average Trading Volume: 10,054,526
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.03B
For an in-depth examination of 2142 stock, go to TipRanks’ Overview page.